文献速递疼痛医学

阿米替林重复给药治疗神经病理性疼痛:对去甲肾上腺素能下行抑制系统的调节

Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System.
PubMed 文献 · Anesth Analg · 2017-01-01

本研究在大鼠L5脊神经结扎模型上,比较阿米替林、度洛西汀、普瑞巴林和加巴喷丁连续5天腹腔注射的抗痛觉过敏效应,并用DSP-4毁损去甲肾上腺素能纤维。结果显示,度洛西汀、普瑞巴林和加巴喷丁的效应被DSP-4逆转,而阿米替林的效应未被逆转,且不被α2拮抗剂idazoxan逆转。

要点

  • 阿米替林连续5天给药在去甲肾上腺素能下行抑制系统受损时仍产生抗痛觉过敏效应。
  • 度洛西汀、普瑞巴林和加巴喷丁的抗痛觉过敏效应依赖于去甲肾上腺素能下行抑制系统。
  • 阿米替林可激活蓝斑去甲肾上腺素能神经元并增加蓝斑和脊髓背角DβH免疫反应性。

核心结论

  • 连续5天注射阿米替林在去甲肾上腺素能下行抑制系统受抑制时仍可产生抗神经病理性疼痛的痛觉过敏效应。
  • 阿米替林可激活蓝斑神经元并增加SNL大鼠去甲肾上腺素能纤维密度。
  • 阿米替林可能增强需要正常下行去甲肾上腺素能抑制才能产生镇痛效果的药物(如SNRI和加巴喷丁类药物)的镇痛作用。

研究设计与样本

  • 大鼠L5脊神经结扎(SNL)模型,术后7天给予DSP-4(50 mg/kg)毁损去甲肾上腺素能纤维。
  • SNL术后21天起连续5天每日腹腔注射阿米替林(10 mg/kg)、度洛西汀(10 mg/kg)、普瑞巴林(10 mg/kg)或加巴喷丁(50 mg/kg)。
  • 采用缩足阈值评估药物对SNL后痛觉过敏的影响,并用c-Fos和DβH免疫组化检测蓝斑和脊髓。

主要发现

  • 连续5天注射阿米替林、度洛西汀、普瑞巴林和加巴喷丁均对SNL大鼠产生抗痛觉过敏效应(P < .001;阿米替林估计治疗效应[99%置信区间]:59.9 [35.1-84.7] g)。
  • DSP-4预处理可逆转度洛西汀、普瑞巴林和加巴喷丁的抗痛觉过敏效应(分别P < .001)。
  • DSP-4预处理后阿米替林仍产生抗痛觉过敏效应(P < .001,59.7 [30.0-89.3] g),且该效应不被α2肾上腺素受体拮抗剂idazoxan(30 μg)逆转。
  • 连续5天注射阿米替林增加SNL大鼠(无论是否DSP-4预处理)蓝斑去甲肾上腺素能神经元中c-Fos免疫反应阳性细胞比例(分别P < .001)。
  • 连续5天注射阿米替林增加SNL大鼠蓝斑和脊髓背角DβH免疫反应性(分别P < .001);DSP-4预处理后DβH免疫反应性显著降低(P < .001)。

临床怎么用

  • 阿米替林在去甲肾上腺素能下行抑制系统病理功能障碍时仍可能产生镇痛作用。
  • 阿米替林可能增强SNRI和加巴喷丁类药物等需要正常下行去甲肾上腺素能抑制的镇痛药的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The tricyclic antidepressant amitriptyline, the serotonin and noradrenaline reuptake inhibitor duloxetine, and gabapentinoids are first-line drugs for treatment of neuropathic pain. The analgesic effect of these drugs relates to brainstem-spinal descending noradrenergic systems. However, amitriptyline utilizes a variety of mechanisms for analgesia in neuropathic pain, and it is unclear which mechanism is most important. In the present study, we investigated the role of descending noradrenergic systems in the analgesic effect of these drugs for treatment of neuropathic pain. We also examined whether amitriptyline modifies the descending noradrenergic systems. METHODS: Seven days after L5 spinal nerve ligation (SNL), rats received N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4, 50 mg/kg) to degenerate noradrenergic fibers. The rats then received 5 daily intraperitoneal injections of amitriptyline (10 mg/kg), duloxetine (10 mg/kg), pregabalin (10 mg/kg), or gabapentin (50 mg/kg) from 21 days after SNL surgery. Paw withdrawal thresholds were determined to assess the effect of the drugs on hyperalgesia after SNL. To determine whether 5 daily injections of amitriptyline activated noradrenergic neurons in the locus coeruleus (LC) and spinal cord with or without DSP-4 treatment, we performed immunohistochemistry using antibodies for c-Fos and dopamine beta-hydroxylase (DβH). RESULTS: Five daily injections of amitriptyline, duloxetine, pregabalin, and gabapentin exerted antihyperalgesic effects in SNL rats (P < .001; estimated treatment effect of amitriptyline [99% confidence interval]: 59.9 [35.1-84.7] g). The antihyperalgesic effects of duloxetine, pregabalin, and gabapentin were reversed by pretreatment with DSP-4 (P < .001, respectively). However, antihyperalgesia was still observed after treatment of amitriptyline in SNL rats with DSP-4 pretreatment (P < .001, 59.7 [30.0-89.3] g), and this analgesic effect was not reversed by the α2-adrenoceptor antagonist idazoxan (30 μg). Additionally, 5 daily injections of amitriptyline increased the ratio of c-Fos-immunoreactive (IR) cells in noradrenergic LC neurons in SNL rats with or without DSP-4 pretreatment (P < .001, respectively). Five daily injections of amitriptyline increased DβH-IR in the LC and the spinal dorsal horn of SNL rats (P < .001, respectively). With DSP-4 pretreatment, DβH-IR was dramatically decreased with or without 5 daily injections of amitriptyline (P < .001). CONCLUSIONS: Five daily injections of amitriptyline produced antihyperalgesic effects against neuropathic pain despite suppression of noradrenergic descending inhibitory systems. Amitriptyline activated LC neurons and increased noradrenergic fibers density in SNL rats. These results suggest that amitriptyline could still produce analgesia under pathological dysfunction of the descending noradrenergic system. Amitriptyline may enhance the analgesic effect of drugs for neuropathic pain that require normal descending noradrenergic inhibition to produce analgesia, such as serotonin and noradrenaline reuptake inhibitors and gabapentinoids.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Hiroki T, Suto T, Saito S, et al. Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System. Anesth Analg. 2017. PMID: 28787345. doi:10.1213/ANE.0000000000002352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。